Anheuser-Busch InBev SA/NV Sponsored ADR Stock News

Chiefs Fans Prefer Michelob Ultra and Coors, Eagles Fans Reach for Miller and Corona; Viewers Mixed on Taylor Swift: 28% Dislike Attention She Receives, 21% Say She Brings New Fans to NFL Chiefs Fans Prefer Michelob Ultra and Coors, Eagles Fans Reach for Miller and Corona; Viewers Mixed on Taylor Swift: 28% Dislike Attention She Receives, 21% Say She Brings New Fans to NFL

We think that Anheuser-Busch InBev stock (NYSE: BUD) is currently a better pick over its peer, Diageo stock (NYSE: DEO). BUD stock trades at 1.6x trailing revenues, versus 3.3x for DEO.

Anheuser-Busch increases investment in Super Bowl LIX and returns with the iconic brands, the star power and the memorable stories that fans crave ST. LOUIS , Jan. 16, 2025 /PRNewswire/ -- For decades, Anheuser-Busch (NYSE:BUD) brands have been in hand, on screen and raised in celebration of the most iconic moments in sports and entertainment.

ST. LOUIS--(BUSINESS WIRE)--Anheuser-Busch and 1st Phorm, a premier sports nutrition and supplements company, today announced plans to form a new partnership aimed at fueling new innovations within the rapidly growing energy drinks and related beverage segments. Brendan Whitworth, CEO of Anheuser-Busch, stated, "Building on our commitment to consistently deliver quality and innovation, Anheuser...

BUD continues to face a lack of bullish support, thanks to the numerous headwinds across FX devaluation, declining alcohol volumes sold on YoY basis, and potential cancer label. The industry's secular decline may also be attributed to the growing acceptance/availability of cannabis and higher demand for zero-proof/healthier alcohol. Even so, BUD has been reporting sequentially growing volumes s...

Potential tariffs, a surgeon general health warning, and persistent inflation concerns among consumers are weighing on the businesses.

Americans consumed over 62 million cases of ready-to-drink spirits in 2023, an increase of almost 25% from 2022.

Popular alcohol producers had a bumpy morning as investors reacted to an advisory from the U.S. Surgeon General about alcohol and cancer.